Insulin-replacement medications - revenues 2010
This statistic shows global revenues from top insulin-replacement medications in 2010. The medication Humalin brought in 0.78 billion euros in revenue worldwide.
Advertisement
Advertisement
Revenues from leading insulin-replacement medications in 2010 (in billion euros)
Log in or register to access precise data.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$1,299 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Biogen's top products based on revenue 2022-2024
- Premium Statistic Italy: number of R&D employees of biotech pharma companies 2014-2017
- Premium Statistic AbbVie key product revenues 2023-2024
- Premium Statistic Top global biotech companies - net sales 2023
- Premium Statistic Top global biotech companies selection based on market cap 2025
- Premium Statistic Share of biologic sales of top 10 biologics in Canada 2018
- Basic Statistic Share of pharmaceutical sales of top biologics in Canada 2018
- Premium Statistic Canada's biologics sales 2009-2018
- Premium Statistic Biologic medicines sales distribution by treatment costs in Canada 2018
- Premium Statistic Biologic share of total pharmaceutical sales in select countries 2018
About the region
10
- Premium Statistic Gilead Sciences' top products based on revenue 2022-2024
- Basic Statistic Gilead Sciences net income 2020 to 2024
- Premium Statistic Gilead Sciences revenue 2006-2024
- Basic Statistic Rate of return on biopharma R&D late stage pipeline 2013-2024
- Basic Statistic Net sales of Recipharm 2009-2024
- Premium Statistic Boehringer Ingelheim's distribution of revenue by business 2016-2024
- Premium Statistic Boehringer Ingelheim's revenues by business area 2016-2024
- Basic Statistic Boehringer Ingelheim's R&D expenditure as a percentage of revenue 2004-2024
- Basic Statistic Boehringer Ingelheim's top animal health product revenues 2023-2024
- Premium Statistic Merck & Co.'s top-selling drugs 2024
Selected statistics
6
- Basic Statistic Celgene's revenue and net income 2006-2018
- Premium Statistic Key figures on established biotech centers worldwide 2012-2016
- Premium Statistic R&D expenditure in U.S. biotechnology 2009-2010 by type
- Premium Statistic MorphoSys' revenue 2006-2023
- Basic Statistic MorphoSys' research & development expenditure 2006-2023
- Premium Statistic Biotech company distribution by geographical location
Other regions
10
- Basic Statistic Revenue of top growing private specialty pharmacies in U.S. 2018
- Basic Statistic Usage of infliximab biosimilars in select countries 2018
- Basic Statistic Number of applications for drug reimbursement in Denmark 2013-2022
- Basic Statistic Employees at Sobi 2013-2024
- Basic Statistic Canada's biologics sales per capita 2009-2018
- Premium Statistic Phoenix Group: revenue 2004-2025
- Premium Statistic Roche Farma S.A. sales value in Spain 2012-2022
- Basic Statistic Number of pharmaceutical preparation enterprises in Norway 2016-2023
- Basic Statistic Value of pharmaceutical sales in Belgium 2010-2022
- Premium Statistic Sales share of Novo Nordisk's drugs in Chinese diabetes market 2023, by segment
Related statistics
10
- Basic Statistic Top revenue growth rates of private specialty pharmacies U.S. 2015-2018
- Basic Statistic Revenue of Sobi 2009-2024
- Premium Statistic Average peak sales forecast per new biopharmaceutical asset 2013-2024
- Basic Statistic Medicine spending share globally in 2007, 2022, and 2027, by country group
- Premium Statistic Top specialty drug pharmacies in the U.S. by revenue 2024
- Premium Statistic Top specialty drug pharmacies in the U.S. based on market share 2024
- Basic Statistic Annual compensation in U.S. biopharmaceutical industry vs. national average 2022
- Premium Statistic Sectors with largest supply inputs on the U.S. biopharmaceutical industry 2022
- Basic Statistic Sectors with largest jobs impacts by U.S. biopharma industry 2022
- Basic Statistic Biopharmaceutical industry employee number by subsector U.S. 2022
Further related statistics
10
- Merck & Co total assets 2020 to 2024
- Pfizer revenues in the U.S. and abroad 2009-2024
- Merck & Co cash dividends declared 2006-2024
- Merck & Co. R&D expenditure 2006-2024
- Sanofi total assets 2019 to 2023
- AstraZeneca revenue from product Pulmicort 2006-2024
- Johnson & Johnson employees 2004-2024
- Annual revenue of Sinopharm 2010-2024
- Annual revenue of Shanghai Pharmaceuticals 2011-2024
- Global pharmaceutical pipeline by therapy area 2013-2017
Further Content: You might find this interesting as well
Statistics
- Merck & Co total assets 2020 to 2024
- Pfizer revenues in the U.S. and abroad 2009-2024
- Merck & Co cash dividends declared 2006-2024
- Merck & Co. R&D expenditure 2006-2024
- Sanofi total assets 2019 to 2023
- AstraZeneca revenue from product Pulmicort 2006-2024
- Johnson & Johnson employees 2004-2024
- Annual revenue of Sinopharm 2010-2024
- Annual revenue of Shanghai Pharmaceuticals 2011-2024
- Global pharmaceutical pipeline by therapy area 2013-2017
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$1,299 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Evotec. (March 24, 2011). Revenues from leading insulin-replacement medications in 2010 (in billion euros) [Graph]. In Statista. Retrieved June 27, 2025, from https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/
Evotec. "Revenues from leading insulin-replacement medications in 2010 (in billion euros)." Chart. March 24, 2011. Statista. Accessed June 27, 2025. https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/
Evotec. (2011). Revenues from leading insulin-replacement medications in 2010 (in billion euros). Statista. Statista Inc.. Accessed: June 27, 2025. https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/
Evotec. "Revenues from Leading Insulin-replacement Medications in 2010 (in Billion Euros)." Statista, Statista Inc., 24 Mar 2011, https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/
Evotec, Revenues from leading insulin-replacement medications in 2010 (in billion euros) Statista, https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/ (last visited June 27, 2025)
Revenues from leading insulin-replacement medications in 2010 (in billion euros) [Graph], Evotec, March 24, 2011. [Online]. Available: https://www.statista.com/statistics/274506/revenues-from-insulin-replacement-medication/
Advertisement